دورية أكاديمية

Effectiveness and safety of dupilumab in patients with chronic rhinosinusitis with nasal polyps and associated comorbidities: a multicentric prospective study in real life

التفاصيل البيبلوغرافية
العنوان: Effectiveness and safety of dupilumab in patients with chronic rhinosinusitis with nasal polyps and associated comorbidities: a multicentric prospective study in real life
المؤلفون: Nettis E., Brussino L., Patella V., Bonzano L., Detoraki A., Di Leo E., Sirufo M. M., Caruso C., Lodi Rizzini F., Conte M., Yacoub M. -R., Triggiani M., Ridolo E., Macchia L., Rolla G., Brancaccio R., De Paulis A., Spadaro G., Di Bona D., D'Uggento A. M., Ginaldi L., Gaeta F., Nucera E., Jaubashi K., Villalta D., Dagna L., Ciotta D., Pucciarini F., Bagnasco D., Celi G., Chieco Bianchi F., Cosmi L., Costantino M. T., Crivellaro M. A., D'Alo S., del Biondo P., Del Giacco S., Di Gioacchino M., Di Pietro L., Favero E., Gangemi S., Guarnieri G., Heffler E., Leto Barone M. S., Lombardo C., Losa F., Matucci A., Minciullo P. L., Parronchi P., Passalacqua G., Pucci S., Rossi O., Salvati L., Schiappoli M., Senna G., Vianello A., Vultaggio A., Baoran Y., Incorvaia C., Canonica G. W.
المساهمون: Nettis, E., Brussino, L., Patella, V., Bonzano, L., Detoraki, A., Di Leo, E., Sirufo, M. M., Caruso, C., Lodi Rizzini, F., Conte, M., Yacoub, M. -R., Triggiani, M., Ridolo, E., Macchia, L., Rolla, G., Brancaccio, R., De Paulis, A., Spadaro, G., Di Bona, D., D'Uggento, A. M., Ginaldi, L., Gaeta, F., Nucera, E., Jaubashi, K., Villalta, D., Dagna, L., Ciotta, D., Pucciarini, F., Bagnasco, D., Celi, G., Chieco Bianchi, F., Cosmi, L., Costantino, M. T., Crivellaro, M. A., D'Alo, S., del Biondo, P., Del Giacco, S., Di Gioacchino, M., Di Pietro, L., Favero, E., Gangemi, S., Guarnieri, G., Heffler, E., Leto Barone, M. S., Lombardo, C., Losa, F., Matucci, A., Minciullo, P. L., Parronchi, P., Passalacqua, G., Pucci, S., Rossi, O., Salvati, L., Schiappoli, M., Senna, G., Vianello, A., Vultaggio, A., Baoran, Y., Incorvaia, C., Canonica, G. W.
بيانات النشر: BioMed Central Ltd
سنة النشر: 2022
مصطلحات موضوعية: abdominal pain,adult,allergy,arthralgia,Article,asthenia,Asthma Quality of Life Questionnaire,bilateral endoscopic nasal polyp score,body weight gain,chronic rhinosinusitis,clinical immunology,cohort analysis,conjunctivitis,Dermatology Life Quality Index,diarrhea,disease association,dizziness,drug efficacy,drug safety,drug tolerability,Eczema Area and Severity Index,female,forced expiratory volume,headache,human,Italy,loading drug dose,major clinical study,male,middle aged,nausea,nose polyp,observational study,perennial rhinitis,prospective study,respiratory tract disease assessment,Rhinitis Control Scoring System,rhinoconjunctivitis quality of life questionnaire,sino-nasal outcome test-22,Urticaria Activity Score
الوصف: Background: Biologics are currently one of the main treatment options for a number of diseases. The IgG4 monoclonal antibody dupilumab targets the Interleukin-4 receptor alpha chain, thus preventing the biological effects of the cytokines IL-4 and IL-13, that are essential for the Th2 response. Several controlled trials showed that dupilumab is effective and safe in patients with atopic dermatitis (AD), severe asthma and chronic rhinosinusitis with nasal polyps (CRSwNP), thus resulting in approval by regulatory agencies. Aim of the study was to evaluate the efficacy and safety of dupilumab in adult patients with CRSwNP stratified by common overlapping comorbid conditions. Methods: We performed a multicenter, observational, prospective study enrolling adult patients with severe CRSwNP who had started dupilumab treatment in the context of standard care from January 2021 to October 2021. Data were collected from twentynine Italian secondary care centers for allergy and clinical immunology, all of which were part of the Italian Society of Allergy, Asthma and Clinical Immunology (SIAAIC). A number of efficacy parameters were used. Patient data were compared using the Wilcoxon test for paired data. All statistical analyses were performed with SPSS version 20 (IBM, Armonk, NY, USA). Results: In total, 82 patients with nasal polyposis were identified. A significant improvement was detected for all the applied efficacy parameters, i.e. 22-item Sino-Nasal Outcome Test (SNOT-22) and bilateral endoscopic nasal polyp score (NPS) scores for CRSwNP, Rhinitis Control Scoring System (RCSS) and Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) scores for allergic perennial rhinitis, Forced Expiratory Volume in the 1st second (FEV1) and Asthma Quality of Life Questionnaire (AQLQ) scores for asthma, Eczema Area and Severity Index (EASI) and Dermatology Life Quality Index (DLQI) scores for AD. A non-significant improvement was also obtained in the Urticaria Activity Score over 7days (UAS7) for chronic spontaneous urticaria. ...
نوع الوثيقة: article in journal/newspaper
اللغة: English
العلاقة: volume:20; issue:1; numberofpages:9; journal:CLINICAL AND MOLECULAR ALLERGY; https://hdl.handle.net/20.500.11768/135756Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85130345254; https://clinicalmolecularallergy.biomedcentral.com/articles/10.1186/s12948-022-00171-2Test
DOI: 10.1186/s12948-022-00171-2
الإتاحة: https://doi.org/20.500.11768/135756Test
https://doi.org/10.1186/s12948-022-00171-2Test
https://hdl.handle.net/20.500.11768/135756Test
حقوق: info:eu-repo/semantics/openAccess
رقم الانضمام: edsbas.DA8FD126
قاعدة البيانات: BASE